The Top Line

The Top Line

By Fierce Life SciencesNewsBusiness News
Download on the App Store

The Top Line episodes

  • Why Diagnostic-Driven Therapies Still Miss Eligible Patients (Sponsored)

    The promise of precision medicine depends on more than scientific innovation. It also depends on whether eligible patients can be identified, tested and connected to the most appropriate treatment. In this episode of The Top Line, host Kelly Hogan is joined by Susanne Munksted, chief growth officer at Diaceutics, and Jordan Clark, chief customer officer, to discuss why many diagnostic-driven therapies still fail to reach their full potential.

    Drawing on findings from Diaceutics' practice gap studies, the conversation explores where patients are being lost across the diagnostic pathway and why improvements in testing have not always translated into better treatment decisions. The guests discuss increasing healthcare complexity, expanding biomarker requirements and the challenges clinicians face when making treatment decisions under time pressure.

    See omnystudio.com/listener for privacy information.

    14 min
  • MrBeast, Snapchat, AI and more: Pharma marketing’s pulse check

    As Fierce Pharma Week approaches, the Fierce Pharma Marketing team is taking stock of some of the biggest trends reshaping how drugmakers and healthcare agencies reach audiences.

    In this week’s episode of “The Top Line,” Fierce’s Ben Adams and Zoey Becker discuss how pharma marketing is evolving across social media, creative work and agency strategy. They dig into the changing approach to HIV marketing, pharma’s experiments with platforms including Snapchat, and what a collaboration with MrBeast says about the industry’s efforts to reach new audiences.

    They also examine how healthcare agencies are putting AI to work, pharma’s return to the winner’s circle at Cannes and why Novo Nordisk built a maze along the River Thames in London this summer. The conversation comes as Fierce Pharma Week approaches Sept. 14-17 in Philadelphia.

    To learn more about the topics in this episode: 

    • YouTuber MrBeast welcomes Amgen to the channel, kicking off pediatric cancer funding effort
    • Inside agency view: Real Chemistry’s Frank Mazzola on audience nuance and rewarding creativity
    • Snapchat creates ad format to support pharma disclosure needs
    • Novo Nordisk asks public to ‘Meet Me in the Middle’ in new obesity experience installation
    • Women’s ‘new health ecosystem’ takes shape on Reddit: report 

    See omnystudio.com/listener for privacy information.

    22 min
  • What did we learn from Big Pharma’s Q2 results?

    Earnings calls are a chance to catch up with the latest developments across Big Pharma and beyond, and last quarter was no different. From the rollout of AI to the oral GLP-1 battle between Novo Nordisk and Eli Lilly and new leadership at Sarepta and Sanofi, it feels like the opportunities and challenges for biopharma have never been greater.

    In this week’s episode of "The Top Line," Fierce Pharma Senior Editor Fraiser Kansteiner and Fierce Biotech Senior Editor James Waldron share their takeaways from another whirlwind season of earnings calls. Alongside a Q2 scorecard breakdown, the Fierce editors discuss how several new CEOs are finding their footing, which drugs appear poised to cross the $1 billion sales threshold in 2026 and more.

    To learn more about the topics in this episode: 

    • Biopharma saw a Q2 sales boom led by Lilly, Sanofi, Regeneron and Astellas 
    • Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
    • Novo CEO has 'no doubt' on eventual share price recovery as Wegovy pill continues to wow
    • Sarepta’s new CEO Michael Severino faces critical milestones to prove growth

    See omnystudio.com/listener for privacy information.

    33 min
  • How consumerization is reshaping pharma marketing (Sponsored)

    Consumerization is changing how patients engage with healthcare, and pharma companies may need to rethink how they approach awareness, diagnosis and commercialization.

    In this sponsored episode of The Top Line, host Irena Luo is joined by Rachel Stoll, Managing Partner, Growth & Innovation at Princeton10, and Kevin Nalty, Vice President of Strategy at Princeton10, to discuss how evolving patient behaviors are reshaping the healthcare journey. Together, they explore the impact of GLP-1s, telemedicine, AI, wellness technologies and other low-friction healthcare experiences that are raising expectations for convenience and accessibility.

    The conversation examines emerging gaps between health awareness and clinical diagnosis, the role of wellness tools and health data, and why some patients delay or avoid care altogether. The guests also discuss opportunities for pharma brands to rethink disease awareness, improve navigation to diagnosis and treatment, and borrow engagement strategies from successful consumer platforms that encourage long-term behavior change.

    Listen to hear practical insights on how brand teams can adapt their commercial strategies, identify hidden friction points and better meet the needs of today's healthcare consumer.

    See omnystudio.com/listener for privacy information.

    18 min
  • A genomics library for the AI era

    Having spent 14 years building out its capacity, Regeneron Genetics Center—the genomic research branch of the Tarrytown, New York-based pharma—is a pro when it comes to the sort of target validation work central to the field today. Now, as RGC continues the massive expansion of its genetic database, the center’s unique ability to interpret that trove of data could give it an edge in the age of AI-powered drug development.

    In this week’s episode of "The Top Line," Fierce’s Fraiser Kansteiner sits down with Andy Deubler, chief business and administrative officer at Regeneron Genetics Center, to discuss the role RGC plays in the larger Regeneron model, as well as where the center could be headed as drug development pushes into new technological frontiers. Aside from the data interpretation advantage RGC believes it holds in the AI era, Deubler also discusses how the unit’s ongoing genetic research has helped deliver recent breakthroughs like the hearing loss gene therapy Otarmeni.

    To learn more about the topics in this episode: 

    • Regeneron ushers in new genetic medicine era with groundbreaking gene therapy approval 
    • J. Craig Venter launches genomics startup designed to boost diagnostic insights
    • Genomics inks partnership deal with Greywolf to assess gene datasets
    • How a new tool for large-scale gene editing could power novel genetic medicines

     

    In global life sciences, insight isn’t the problem—execution is. 

    Disconnected dashboards, siloed teams and fragmented workflows make it harder to act—consistently, compliantly and at scale. 

    ZAIDYN by ZS closes that gap. 

    ZAIDYN is the Life Sciences Intelligence Platform that embeds intelligence in the flow of work, based on domain expertise and agentic AI across commercial, medical, patient and content work.

    Trusted by more than 150 life sciences organizations across over 100 countries, ZAIDYN is built for global scale, regulatory compliance and trusted AI—so teams act together across brands, markets and channels. 

    ZAIDYN. Move beyond reporting to intelligent action. 

    Learn more at ZAIDYN.ai

    See omnystudio.com/listener for privacy information.

    24 min
  • The next frontier in patient support: Connected data, AI and personalized engagement (Sponsored)

    The future of patient support may depend less on how much data organizations collect and more on how effectively they connect, govern and activate it. In this sponsored episode of The Top Line, host Stephanie Butler speaks with ZS principals Asheesh Shukla and Kirti Prakash about the changing role of patient data in life sciences and what it will take to support more personalized engagement at scale.

    The conversation examines several shifts reshaping the industry, including the move from reactive care to proactive intervention, the growing role of AI-powered experiences and the increasing importance of trust, consent and compliance in patient engagement. As organizations invest in new technologies, the speakers contend that success will depend on creating connected data foundations that can deliver timely, actionable insights across the patient journey.

    Listeners will hear practical guidance on structuring data for actionability, building AI-ready capabilities and designing governance models that support both innovation and accountability. The discussion closes with a look at where patient services may be headed next and why organizations that prepare now will be better positioned to improve patient experiences and outcomes in the years ahead.

    See omnystudio.com/listener for privacy information.

    27 min
  • Novo Nordisk’s CFO on the oral Wegovy rollout and beyond

    Novo Nordisk’s second-quarter earnings results this week were closely watched by analysts and investors eager to see whether the rollout of oral Wegovy could neutralize concerns about the pharma’s pipeline.

    Fierce spoke to Novo’s chief financial officer, Karsten Munk Knudsen, to dig into the figures, including the reasons behind the company’s decision to raise its full-year guidance and the launch of oral Wegovy across Europe.

    In the candid conversation, Knudsen also reflected on Novo’s “rollercoaster” journey in obesity, his approach to pursuing long-term growth for the company and why he’s “still optimistic” about CagriSema despite recent setbacks.

    To learn more about the topics in this episode: 

    • Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data
    • Novo CEO has 'no doubt' on eventual share price recovery as Wegovy pill continues to wow
    • ‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO

    See omnystudio.com/listener for privacy information.

    21 min
  • Inside Noble’s connected approach to patient support (Sponsored)

    The continued shift toward self-administered therapies is changing how pharmaceutical companies think about patient support. While access and affordability remain priorities, a growing share of industry attention is focused on the patient experience itself, particularly during the critical transition from prescription to successful treatment initiation.

    In this episode of The Top Line, Adam Shain, Vice President and Head of Business Transformation and Growth and Government Affairs Lead at Noble, an Aptar Pharma company, examines why patient onboarding, device training, and engagement strategies are increasingly being viewed as interconnected components of a broader patient experience. Drawing from Noble's work in self-administration support, Shain discusses the importance of incorporating patient insights into program design, the evolving complexity of at-home treatment models, and the industry's growing focus on adherence and long-term treatment success.

    See omnystudio.com/listener for privacy information.

    16 min
  • Psychedelics, peptides and GLP-1s

    Is biotech taking a trip to the world of psychedelic drugs? Why is Novo Nordisk going after Eli Lilly’s Zepbound ads? And what are peptides? 

    This week on "The Top Line," Fierce's Zoey Becker, Will Maddox and Kevin Dunleavy chat about some of the biggest recent stories. From a psychedelics acquisition that could spark more movement in the emerging field to an advisory committee meeting on peptides shrouded in political controversy to a lawsuit between the two major obesity drugmakers, we’ll catch you up on the latest developments shaking up the biopharma world.

    To learn more about the topics in this episode: 

    • ‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics 
    • UPDATE: Peptides favored on 1st day of closely watched FDA compounding adcomm
    • Peptide adcomm Day 2: Emideltide voted down in panel's 1st pushback
    • Novo Nordisk files lawsuit accusing rival Eli Lilly of running ‘false and misleading’ GLP-1 ads 
    • Novo escalates Lilly false advertising suit with planned bid to halt comparative ads 

    See omnystudio.com/listener for privacy information.

    26 min
  • GSK’s first lung cancer approval, a new IPO path and more

    This week on "The Top Line," Fierce Healthcare and Life Sciences' editor-in-chief steps behind the microphone for a solo episode highlighting several of the biggest stories in biopharma.

    The episode covers GSK’s first lung cancer approval following its acquisition of Nuvalent, Axiom Biosciences’ unusual plan to list first in Hong Kong before pursuing a Nasdaq co-listing amid a resurgent biotech IPO market, and the U.S. House’s passage of legislation directing the FDA to update its animal testing rules.

    The episode also includes an update from the Fierce newsroom, including the arrival of a new Fierce Biotech staff writer, and a reflection on why human judgment, curiosity and original reporting matter more than ever.

    To learn more about the topics in this episode: 

    • GSK secures first lung cancer approval as FDA clears Jideytro in quick payoff from Nuvalent deal
    • ‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong Kong
    • House passes bill directing FDA to update animal testing rules

    See omnystudio.com/listener for privacy information.

    12 min

About The Top Line

From the publisher's feed

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's…

More shows like The Top Line

Motley Fool Hidden Gems Investing by The Motley Fool

Motley Fool Hidden Gems Investing

3,160 Listeners

WSJ Your Money Briefing by The Wall Street Journal

WSJ Your Money Briefing

1,703 Listeners

WSJ What’s News by The Wall Street Journal

WSJ What’s News

4,349 Listeners

Masters in Business by Bloomberg

Masters in Business

2,167 Listeners

The McKinsey Podcast by McKinsey & Company

The McKinsey Podcast

382 Listeners

Odd Lots by Bloomberg

Odd Lots

2,125 Listeners

Stephanomics by Bloomberg

Stephanomics

349 Listeners

WSJ Tech News Briefing by The Wall Street Journal

WSJ Tech News Briefing

1,635 Listeners

HBR IdeaCast by Harvard Business Review

HBR IdeaCast

132 Listeners

FT Tech Tonic by Financial Times

FT Tech Tonic

102 Listeners

Masters of Scale by WaitWhat

Masters of Scale

3,982 Listeners

Bold Names by The Wall Street Journal

Bold Names

1,426 Listeners

The Readout Loud by STAT

The Readout Loud

338 Listeners

BioCentury This Week by BioCentury

BioCentury This Week

33 Listeners

HBR On Leadership by Harvard Business Review

HBR On Leadership

155 Listeners